Clinical Trial

A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors

Study acronym: PBC102
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CEA-positive advanced malignancies were obtained and the recommended dose and infusion schedule.
Protocol Amendment History 1 change
notable Sponsor changed: Second Affiliated Hospital, School of Medicine, Zhejiang University -> Second Affiliated Hospital, Zhejiang University, School of Medicine 2026-08-09
Trial Details
NCT Number NCT07250386
Lead Sponsor Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators: Chongqing Precision Biotech Co., Ltd
Conditions NSCLC (Advanced Non-small Cell Lung Cancer), Breast Cancer
Enrollment 48 participants
Start Date 2025-10-13
Primary Completion 2028-06-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-11-26